Crystal structures of pure 3-(4-bromo-2-chlorophenyl)-1-(pyridin-4-yl)benzo[4,5]imidazo[1,2-d][1,2,4]triazin-4(3H)-one and contaminated with 3-(4-bromophenyl)-1-(pyridin-4-yl)benzo[4,5]imidazo[1,2-d][1,2,4]triazin-4(3H)-one
Open Access
- 15 August 2017
- journal article
- research article
- Published by International Union of Crystallography (IUCr) in Acta Crystallographica Section E Crystallographic Communications
- Vol. 73 (9) , 1341-1343
Abstract
The side product of the cyclocondensation reaction between ethyl benzimidazole-2-carboxylate and the nitrile imine of the corresponding hydrazonyl chloride, C20H11BrClN5O, crystallized in two crystal forms. Form (1) is a co-crystal of the target compound (without any chlorine substituent) and a side product containing a Cl atom in position 2 of the bromophenyl group, C20H12BrN5O·0.143C20H11BrClN5O. (2) contains the pure side product. The slightly different conformation of the ring systems leads to a different packing of (1) and (2), but both crystal structures are dominated by π–π interactions.Keywords
This publication has 8 references indexed in Scilit:
- Crystal structure refinement withSHELXLActa Crystallographica Section C Structural Chemistry, 2015
- Synthesis of novel 4-(1H-benzimidazol-2-yl)benzene-1,3-diols and their cytotoxic activity against human cancer cell linesArchives of Pharmacal Research, 2011
- Synthesis and anticancer activity of some novel 2-substituted benzimidazole derivativesEuropean Journal of Medicinal Chemistry, 2010
- Design, Synthesis, and In Vitro Antiproliferative Activity of Benzimidazole Analogues for Radiopharmaceutical EfficacyCancer Biotherapy and Radiopharmaceuticals, 2010
- Synthesis and cytotoxicity evaluation of some benzimidazole-4,7-diones as bioreductive anticancer agentsEuropean Journal of Medicinal Chemistry, 2008
- Maribavir: A new Oral Anti-Cytomegalovirus DrugFuture Virology, 2008
- Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trialMolecular Cancer Therapeutics, 2007
- Antiviral drugs for cytomegalovirus diseasesAntiviral Research, 2006